Epizyme

November 8, 2016

Epizyme Updates Clinical Trial Data on Tazemotostat for Mesothelioma, Other Cancers

News

Epizyme has reported recent updates from its clinical-stage programs with the company’s lead candidate, tazemotostat, for the treatment of hematological malignancies and genetically defined solid tumors. Tazemotostat, a first-in-class small molecule, oral ... Read more

August 16, 2016August 16, 2016

First Mesothelioma Patient Treated with Tazemetostat in Global Phase 2 Trial

News

Epizyme announced that researches have initiated treatment of a first patient in the Phase 2 clinical trial of its first-in-class EZH2 inhibitor, tazemetostat, in adults with malignant mesothelioma. EZH2 is an enzyme that induces a type of ... Read more

May 9, 2016May 9, 2016

FDA Approves Request to Test EZH2 Inhibitor, Tazemetostat, in Mesothelioma Patients

News

The U.S. Food and Drug Administration (FDA) recently accepted an Investigational New Drug (IND) application for tazemetostat as a potential treatment of mesothelioma in adults. The decision allows Epizyme, the company developing tazemetostat, ... Read more